Section 689.NEW - [Newly enacted section not yet numbered] [Operative 10/1/2024](1) Consistent with the protocols adopted by the State Board of Pharmacy by rule, as recommended by the Public Health and Pharmacy Formulary Advisory Committee, a pharmacist may test for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and prescribe, dispense and administer treatment, including drug therapy, for SARS-CoV-2.(2) When testing for SARS-CoV-2, a pharmacist may use:(a) A screening procedure that can be safely performed by a pharmacist; and(b) A test that: (A) Guides the pharmacist's clinical decision-making;(B) Is determined by the Centers for Medicare and Medicaid Services to qualify as a waived test under the Clinical Laboratory Improvement Amendments of 1988 (P.L. 100-578, 42 U.S.C. 201 and 263a) or federal regulations adopted pursuant to the Clinical Laboratory Improvement Amendments of 1988 or is approved by the United States Food and Drug Administration; and(C) Is approved by the board by rule for use under this section.(3) A pharmacist may delegate to a pharmacy technician or an intern under the pharmacist's supervision the administrative and technical tasks of performing a task described in subsection (2) of this section.(4) The board may adopt rules as necessary to carry out this section.Added by 2024 Ch. 17,§ 4, eff. 91st day after sine die, op. 10/1/2024.